The Intersection of Biotech, Patent Law, and AI with Dr. Kate Neville, IP Attorney
About this episode
The episode discusses the critical intersection of biotech, patent law, and AI with insights from Dr. Kate Neville.
Recorded October 31, 2025 In this episode of BioTalk Unzipped , Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property. If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening. We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape. Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney. In This Episode We Discuss: • The difference between patent prosecution and patent litigation • Why it is never too early for biotech startups to think about IP • The U.S. one-year grace period vs. Europe’s stricter disclosure rules • What “Freedom to…
More episodes of BioTalk Unzipped
- Active Machine Learning for Drug Discovery & Nanomedicine with Dr. Daniel Reker
- Why Haven’t We Cured Cancer Yet? | Dr. Bob Liu Explains
- Long-acting Cell-Based Gene Therapy, Fabry Disease and Beyond with Glafabra CEO, Dr. Chris Hopkins
- Fail Fast, Learn Faster: Drug Development in Rare Disease with Dr. Binodh DeSilva
- Unlocking Antibody Development with AI with Dr. Pin-Kuang Lai
- The Science and Hope of Brain Cancer with Dr. Robert Thorne, Denali Therapeutics
Explore listener stats, chart rankings, contacts and more on the BioTalk Unzipped podcast page.